Xingyu Chen
Impact in
- Cancer Research top 10%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Molecular Biology top 10%
- RNA modifications and cancer
- Epigenetics and DNA Methylation
Papers in
-
- Epigenetics and DNA Methylation 5
- RNA modifications and cancer 5
- Oncology 21
- Cancer-related Molecular Pathways 4
- Cancer Immunotherapy and Biomarkers 4
- Co-authors
- Ke Cao (15 shared papers)Yuxing Zhu (12 shared papers)Dong He (12 shared papers)Zhanwang Wang (10 shared papers)Mengqing Xiao (9 shared papers)Yaxin Cheng (8 shared papers)Yi Jin (5 shared papers)Chenfang Dong (8 shared papers)
- Journals
- Frontiers in Immunology (6 papers)Theranostics (3 papers)Journal of Experimental & Clinical Cancer Research (3 papers)Frontiers in Oncology (3 papers)Scientific Reports (3 papers)
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Xingyu Chen
114 papers receiving 1.8k citations
Xingyu Chen's Hit Papers
Peers
Comparison fields: 5 of 126
- Cancer Research 255
- Molecular Biology 810
- Immunology 208
- Oncology 195
- Pulmonary and Respiratory Medicine 189
Countries citing papers authored by Xingyu Chen
This map shows the geographic impact of Xingyu Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xingyu Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xingyu Chen more than expected).
Fields of papers citing papers by Xingyu Chen
This network shows the impact of papers produced by Xingyu Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xingyu Chen. The network helps show where Xingyu Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside Xingyu Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 130 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Y chromosome loss in cancer drives growth by evasion of adaptive immunity Hit paper breakdown → | 2023 | 105 |
| 2 | 2021 | 68 | |
| 3 | 2021 | 68 | |
| 4 | 2021 | 66 | |
| 5 | 2022 | 65 | |
| 6 | 2019 | 60 | |
| 7 | 2021 | 55 | |
| 8 | 1991 | 53 | |
| 9 | 2018 | 49 | |
| 10 | 2023 | 43 | |
| 11 | 2018 | 43 | |
| 12 | Long noncoding RNA MALAT1 and its target microRNA-125b are potential biomarkers for Alzheimer's disease management via interactions with FOXQ1, PTGS2 and CDK5. | 2020 | 38 |
| 13 | 2017 | 37 | |
| 14 | 2021 | 34 | |
| 15 | 2019 | 34 | |
| 16 | 2020 | 32 | |
| 17 | 2019 | 29 | |
| 18 | 2020 | 29 | |
| 19 | 2021 | 28 | |
| 20 | 2021 | 27 |
About Xingyu Chen
Xingyu Chen is a scholar working on Molecular Biology, Oncology, Immunology, Pulmonary and Respiratory Medicine and Surgery, having authored 130 papers that have together received 1.8k indexed citations. Recurring topics across this work include Ferroptosis and cancer prognosis (9 papers), Bladder and Urothelial Cancer Treatments (7 papers), Acute Ischemic Stroke Management (6 papers), Epigenetics and DNA Methylation (5 papers), Cancer-related molecular mechanisms research (5 papers), RNA modifications and cancer (5 papers), Cancer-related Molecular Pathways (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). The work is most often cited by research in Cancer Research (255 citations), Molecular Biology (810 citations), Immunology (208 citations), Oncology (195 citations) and Pulmonary and Respiratory Medicine (189 citations). Xingyu Chen has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Ke Cao, Yuxing Zhu, Dong He, Zhanwang Wang, Mengqing Xiao, Yaxin Cheng, Yi Jin, Chenfang Dong, Qianhua Cao and Ruocen Liao. Their work appears in journals such as Frontiers in Immunology, Theranostics, Journal of Experimental & Clinical Cancer Research, Frontiers in Oncology and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.